BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II/III clinical trial for hereditary angioedema (HAE); BCX7353, an oral serine protease inhibitor, which is in Phase II clinical trial for HAE; and other second generation HAE compounds, an oral serine protease inhibitor, which is in preclinical stage. The company's product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in preparation to file for regulatory approval. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; and Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Down 23% pre-market. Announced positive results on phase 2 trial, not sure why it's down BioCryst Pharma (BCRX) Announces Positive Interim Results from its APeX-1 Trial BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced results from an interim analysis of its Phase 2 APeX-1 trial in hereditary angioedema (HAE). APeX-1 is a dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered once daily (QD) BCX7353 for 28 days, as a preventative treatment to reduce the frequency of attacks in HAE patients. Read full article here: http://www.streetinsider.com/Corpor...m+Results+from+its+APeX-1+Trial/12595042.html
Good day for any longs who got in today Wish I would have acted on my last post saying positive news, but stock way down...
BioCryst Pharmaceuticals ($BCRX) is likely to see early strength after announcing that Mundipharma has obtained regulatory approval of Mundesinefor the treatment of relapsed/refractory PTCL by the Ministry of Health, Labor and Welfare in Japan.
shares of BioCryst Pharmaceuticals (BCRX) rose 19.1% to $6.11. The Research Triangle Park, N.C.-based firm on Thursday announced additional positive results from a second interim analysis of a phase two study of BCX7353 as a preventative treatment to reduce the frequency of attacks in patients with hereditary angioedema.
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE https://finance.yahoo.com/news/biocryst-announces-positive-results-apex-100000259.html
